Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | THRB | P10828 | 1/20 | 0.73 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 3/20 | 0.39 |
| ▸ | ARG2 | P78540 | 3/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.38 |
| ▸ | PPARG | P37231 | 7/20 | 0.38 |
| ▸ | PPARD | Q03181 | 7/20 | 0.38 |
| ▸ | PPARA | Q07869 | 7/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9005565 | 1.00 | ALDH1A1 (0.73) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL9586044 | 0.89 | CYP1A2 (0.74) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL348479 | 0.89 | MEN1 (0.54) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL9005521 | 0.88 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL1300786 | 0.88 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL27645402 | 0.86 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL179812 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL5485081 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL1308931 | 0.84 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL9005538 | 0.84 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2ACYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0925294-B3 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20160096818-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNFALPHA LEVELS | CELGENE CORPORATION | 2016-04-07 | — | — | US | disclosed |
| EP-2859895-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORPORATION (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-2305663-B1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORP (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140187584-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and -1-Oxoisoindolines and Method of Reducing TNFalpha Levels | CELGENE CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130030021-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and 1-Oxoisoindolines and Method of Reducing TNFalpha Levels | CELGENE CORPORATION (US) | 2013-01-31 | — | — | US | disclosed |
| EP-1956017-B1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and method of reducing TNF alpha levels | CELGENE CORP (US) | 2013-01-23 | — | — | EP | disclosed |
| US-8288415-B2 | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione | CELGENE CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-8158653-B2 | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline | CELGENE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2177517-B1 | Amino substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimide for reducing TNF alpha levels | CELGENE CORP (US) | 2011-10-26 | — | — | EP | disclosed |
| US-6476052-B1 | Isoindolines, method of use, and pharmaceutical compositions | CELGENE CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-6395754-B1 | ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS, ANTIPYRETICS | CELGENE CORPORATION, ET AL. | 2002-05-28 | — | — | US | disclosed |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2002-04-18 | — | — | US | disclosed |
| US-6335349-B1 | AGENTS THAT REDUCE LEVELS OF TUMOR NECROSIS FACTOR; ANTICARCINOGENIC AND ANTIINFLAMMATORY AGENTS; TREATMENT OF AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2002-01-01 | — | — | US | disclosed |
| US-6316471-B1 | TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6281230-B1 | TREATING INFLAMMATION, INFLAMMATORY DISEASE OR AUTOIMMUNE DISEASE IN A MAMMAL | CELGENE CORPORATION | 2001-08-28 | — | — | US | disclosed |
| EP-0984955-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNF$g(a) LEVELS | Gelgene Corporation (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0925294-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998054170-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNFα LEVELS | CELGENE CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998003502-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096818-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNFALPHA LEVELS | TNF, NFKBIA, TRAF2 | ALDH1A1 1232/4885MEN1 4082/4885KMT2A 3091/4885 |
| US-20140187584-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and -1-Oxoisoindolines and Method of Reducing TNFalpha Levels | TNF, NFKBIA, TRAF2 | ALDH1A1 1232/4885MEN1 4082/4885KMT2A 3091/4885 |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, OPRK1, OPRD1 | ALDH1A1 362/4885MEN1 3963/4885KMT2A 3335/4885 |
| US-20130030021-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and 1-Oxoisoindolines and Method of Reducing TNFalpha Levels | TNF, NFKBIA, TRAF2 | ALDH1A1 1344/4885MEN1 4136/4885KMT2A 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.